TrialInvestigational new drugs2011
A phase II study of 2-methoxyestradiol (2ME2) NanoCrystal® dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC).
Michael R Harrison et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
56 papers cite it
this papercites it